Scholars Central

Review articlePublished 16 Jul 2016

Management of Type 2 diabetes with liraglutide

Authors: Mette Bohl, Ann Overgaard, Anna Pietraszek & Kjeld Hermansen

Diabetes Management

Volume 4 · Issue 2 · Pages 189–201

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Liraglutide is a once daily subcutaneously administered GLP-1 receptor agonist approved for Type 2 diabetes treatment. The standard treatment dose is 1.2 mg/day, but dose titration up to 1.8 mg/day is approved. Liraglutide lowers HbA1c by 0.8–1.6% and causes sustained glucose lowering for up to 2 years. Its effect on glycemic control is superior to that of placebo and several comparator drugs. Liraglutide causes a weight reduction of up to 3.6 kg. Its main adverse effects are transient gastrointestinal symptoms. The risk of onset of hypoglycemia in response to liraglutide is very low. An association with acute pancreatitis cannot be entirely excluded. We await data on its impact on cardiovascular disease. GLP-1 receptor agonists are accepted as a second-line treatment in Type 2 diabetes.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalDiabetes Management
  • SubjectDiabetes & Endocrinology
  • BylineArticles whose byline prints “Mette Bohl”
  • BylineArticles whose byline prints “Ann Overgaard”
  • BylineArticles whose byline prints “Anna Pietraszek & Kjeld Hermansen”